Text this: Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)

  _  __   _    _   __    __   _    _    ______   
 | |/ // | || | || \ \\ / // | || | || |      \\ 
 | ' //  | || | ||  \ \/ //  | || | || |  --  // 
 | . \\  | \\_/ ||   \  //   | \\_/ || |  --  \\ 
 |_|\_\\  \____//     \//     \____//  |______// 
 `-` --`   `---`       `       `---`   `------`